XLV, the Health Care Select Sector SPDR ETF, has reversed sharply this week — falling 3.7% to $158.29 — even as the short position that built aggressively through June shows little sign of meaningful retreat.
The price action is the starkest development since last week's note. The ETF shed nearly 2% on Tuesday alone, erasing much of the rally that made last week look like a turning point for the sector. The month-over-month picture still shows a 2.9% gain, but the weekly slide reframes that as consolidation rather than breakout. Healthcare's recent run on pharmaceutical earnings optimism and drug-pricing tailwinds has at least temporarily stalled.
Short positioning has barely moved despite the selloff, and that disconnect is worth watching closely. Short interest dipped just 0.1% on the week to 5.3% of the float — roughly 13.8 million shares — barely changed from the 13.76 million reported in last week's note. The month-over-month figure tells the fuller story: shorts have grown 34% over 30 days, a build that started from around 9.5 million shares in mid-June and has essentially plateaued near its peak rather than unwinding. The ORTEX short score ticked up to 51.3 from the 49.3 reading cited last week, a modest re-escalation after a brief softening.
The borrow market has tightened noticeably this week, though conditions remain far from stressed. Availability pulled back to 176% from 229% where it stood when last week's note published — a 23% tightening in seven days. That move brings availability closer to the tighter end of the recent range, though it remains well above the 52-week low of 24.2%. Cost to borrow edged down 11% on the week to 0.46%, so the tightening in availability has not yet translated into meaningfully higher borrowing costs. The lending market is firming, not squeezing.
Options positioning offers little directional conviction either way. The put/call ratio runs at 1.26, fractionally below its 20-day average of 1.28 — a z-score of -0.4, essentially neutral. XLV options traders have been consistently put-heavy all year, with the 52-week PCR range running from 0.47 to 2.67, so the current reading reflects the sector's habitual defensive tilt rather than any fresh hedging surge. Protective demand has not accelerated into this week's drop.
On the institutional side, the largest declared holder as of March 31 is Managed Account Advisors with 8.6% of shares, which added 2.9 million shares that quarter. JPMorgan held 6.3% but trimmed by 968,000 shares. Morgan Stanley, Merrill Lynch, and LPL Financial all cut modestly. The mixed flow — one large buyer, several mid-sized sellers — is consistent with the ambivalent price and positioning picture XLV has presented all summer.
The week's central question is whether the price drop finally prompts shorts to cover or instead emboldens further building. With short interest flat despite a 3.7% weekly loss, availability tightening, and the short score nudging higher, the data so far points toward the latter — positioning looks sticky rather than resolved.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
